Tag Archives: Antibody Drug Conjugates

This is the fourth article in a series of five blog posts that are putting ADCs in the spotlight. This article will describe the origins of and obstacles faced during ADCs development from the beginning of the 20th century to today. Please read the introductory post ‘ADCs: What are they and why do they matter?’ before this post, if you are unfamiliar with ADCs. Look out for ‘ADCs: Pipeline & Progress’.

This is the second article in a series of five blog posts that are putting ADCs in the spotlight. This article will describe in detail how an ADCs design can control its function and pharmacology. Please read the introductory post Antibody Drug Conjugates: What are they and why do they matter before this post, if you are unfamiliar with ADCs.

This is the first article in a series of five blog posts that will put the ADCs in the spotlight. This article will summarise ADCs while four subsequent posts will go into more depth. Look out for; ADCs: Function & Pharmacology, ADCs: Pros & Cons, ADCs: Origin & Obstacles, and ADCs: Pipeline & Progress